Cardio Diagnostics Holdings Inc
NASDAQ:CDIO

Watchlist Manager
Cardio Diagnostics Holdings Inc Logo
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
Watchlist
Price: 2.13 USD 78.99% Market Closed
Market Cap: $3.9m

Cardio Diagnostics Holdings Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cardio Diagnostics Holdings Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Baker Hughes Co
NASDAQ:BKR
Other Items
-$771m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Schlumberger NV
NYSE:SLB
Other Items
$282m
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Halliburton Co
NYSE:HAL
Other Items
-$71m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-24%
Symbotic Inc
NASDAQ:SYM
Other Items
-$271.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Reddit Inc
NYSE:RDDT
Other Items
-$212.2m
CAGR 3-Years
36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardio Diagnostics Holdings Inc
Glance View

Market Cap
3.9m USD
Industry
N/A

Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.

CDIO Intrinsic Value
0.04 USD
Overvaluation 98%
Intrinsic Value
Price

See Also

Back to Top